 |
Indication & Dosage |
| |
| |
| Oral |
| CHRONIC MANAGEMENT OF REVERSIBLE AIRWAYS OBSTRUCTION |
| Adult:
As sulfate: 20 mg 3 or 4 times daily. |
| |
| Oral |
| CHRONIC MANAGEMENT OF REVERSIBLE AIRWAYS OBSTRUCTION |
| Child:
As sulfate: Up to 1 yr: 5-10 mg tid; 1-3 yr: 5-10 mg 4 times daily; 3-12 yr: 40-60 mg daily in divided doses. |
| |
| Oral |
| AV HEART BLOCK AND SINUS BRADYCARDIA |
| Adult:
As sulfate: Up to 240 mg daily in divided doses. |
| |
| Intravenous |
| AV HEART BLOCK AND SINUS BRADYCARDIA |
| Adult:
As sulfate: 250-500 mcg by slow IV inj. |
| |
| Inhalation |
| RELIEF OF ACUTE BRONCHOSPASM |
| Adult:
As sulfate: Metered-dose inhaler: 1 or 2 inhalations (750 mcg); repeat if necessary after not <3 hr. Max: Up to 12 inhalations (9 mg) in 24 hr. Hand nebuliser (5% solution): 10 inhalations. With a nebulising device e.g. intermittent positive-pressure breathing (IPPB) apparatus: 0.2-0.3 ml of a 5% solution diluted up to 2.5 ml physiological saline, administered not more often than every 4 hr. |
| |
| Inhalation |
| RELIEF OF ACUTE BRONCHOSPASM |
| Child:
As sulfate: Metered-dose inhaler: >12 yr: 1 or 2 inhalations (750 mcg); repeat if necessary after not <3 hr. Max in 24 hr: <6 yr: Up to 4 inhalations; 6-12 yr: Up to 8 inhalations; >12 yr: Up to 12 inhalations. Nebuliser: Infants and children: 0.01-0.02 ml of 5% solution; min dose: 0.1 ml; max dose: 0.3 ml diluted in 2-3 ml normal saline every 4-6 hr or more frequently if necessary. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
CV disease (e.g. arrhythmia, hypertension, CHF), DM, glaucoma, hyperthyroidism, hypokalaemia, seizure disorders. Pregnancy and lactation. |
| |
|
| Adverse Drug Reactions |
Tachycardia, nervousness, increased serum glucose, increased potassium levels, tremor, palpitation, headache, dizziness, insomnia, nausea, vomiting, bad taste, heartburn, xerostomia, trembling, muscle cramps, weakness, coughing, pharyngitis, increased diaphoresis, paradoxical bronchospasm, hypertension, chest pain, angina, drowsiness, diarrhoea, taste change. |
| |
|
| Interactions |
Increased risk of malignant arrhythmias with halothane. Effects may be antagonised by b-blockers e.g. propranolol. Duration of bronchodilation may be increased with inhaled ipratropium. Increased adverse effects with MAOIs, TCAs, sympathomimetics. |
| |
|
|
|
